Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Recommendation of “Hold” from Analysts

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been assigned an average recommendation of “Hold” from the twenty-one analysts that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $19.5909.

NTLA has been the subject of several recent analyst reports. Chardan Capital reaffirmed a “buy” rating and issued a $26.00 target price on shares of Intellia Therapeutics in a research report on Friday, February 27th. William Blair raised Intellia Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Monday, March 2nd. Bank of America restated a “neutral” rating on shares of Intellia Therapeutics in a research report on Monday, March 2nd. Wells Fargo & Company lifted their target price on Intellia Therapeutics from $12.00 to $15.00 and gave the company an “equal weight” rating in a research note on Tuesday, March 3rd. Finally, Wolfe Research reiterated a “peer perform” rating on shares of Intellia Therapeutics in a report on Wednesday, November 12th.

Intellia Therapeutics Stock Performance

Shares of NASDAQ:NTLA opened at $13.47 on Friday. The firm has a 50 day simple moving average of $12.51 and a 200 day simple moving average of $13.21. Intellia Therapeutics has a 52 week low of $5.90 and a 52 week high of $28.25. The company has a market cap of $1.59 billion, a PE ratio of -3.52 and a beta of 2.10.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($0.99) by $0.16. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The firm had revenue of $23.02 million for the quarter, compared to analysts’ expectations of $12.17 million. During the same period in the previous year, the company posted ($1.27) EPS. The company’s quarterly revenue was up 78.4% compared to the same quarter last year. On average, equities analysts predict that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Insider Activity at Intellia Therapeutics

In related news, EVP Birgit C. Schultes sold 8,508 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $78,358.68. Following the transaction, the executive vice president directly owned 98,533 shares of the company’s stock, valued at approximately $907,488.93. The trade was a 7.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO John M. Leonard sold 34,146 shares of the stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $314,484.66. Following the completion of the sale, the chief executive officer owned 1,013,339 shares of the company’s stock, valued at approximately $9,332,852.19. The trade was a 3.26% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 53,051 shares of company stock valued at $488,600. Corporate insiders own 3.10% of the company’s stock.

Institutional Trading of Intellia Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Schroder Investment Management Group lifted its holdings in Intellia Therapeutics by 1,593.4% in the 2nd quarter. Schroder Investment Management Group now owns 406,425 shares of the company’s stock worth $3,812,000 after purchasing an additional 382,425 shares during the last quarter. Marex Group plc acquired a new position in Intellia Therapeutics during the second quarter valued at approximately $5,849,000. JPMorgan Chase & Co. grew its holdings in Intellia Therapeutics by 73.0% during the second quarter. JPMorgan Chase & Co. now owns 940,483 shares of the company’s stock valued at $8,822,000 after purchasing an additional 396,858 shares during the last quarter. AXQ Capital LP bought a new position in shares of Intellia Therapeutics in the second quarter valued at approximately $285,000. Finally, SG Americas Securities LLC raised its position in shares of Intellia Therapeutics by 239.7% in the third quarter. SG Americas Securities LLC now owns 131,070 shares of the company’s stock valued at $2,264,000 after purchasing an additional 92,485 shares during the period. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.